The thought on everyone's mind when looking at Amarin (NASDAQ:AMRN) as an investor right now is: What approach is the company going to take in commercializing its new hypertriglyceridemia drug, Vascepa? Many people consider the company a potential acquisition target; others thought it would seek a partnership before going forward. But after the release of yesterday's conference call, the evidence might suggest that it plans to commercialize Vascepa on its own, an option that previously had some investors a little apprehensive. Motley Fool health care analyst Max Macaluso talks in this video about his take on Amarin's strategy going forward and why the CEO's words were well-received by the market.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 10/28/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.